By Callum Keown

Revvity stock jumped 5% ahead of the open Tuesday after the health-sciences company hiked its full-year outlook ahead of earnings early next month.

The company now expects earnings per share to exceed its previous guidance range of $4.90 to $5 in 2025. Wall Street has been expecting EPS of $4.90, according to analysts polled by FactSet.

It's a similar story for revenue in the fourth quarter. Revvity now sees revenue of $772 million in the final three months of the year, beating the analysts' consensus of $757 million. Its full-year revenue estimate of $2.85 billion was also higher than Wall Street's.

The life sciences and diagnostic company released preliminary financial results late Monday ahead of a presentation at the JPMorgan Healthcare Conference Tuesday.

The stock is up more than 7% in 2026, as of Monday's close, but has fallen 9% over the past 12 months. The shares pointed 5% higher at $109 ahead of the open. S&P 500 futures fell 0.1%.

Analysts covering the stock are split -- 48% have a Buy rating, while 48% say Hold, according to FactSet. The average price target of $112.31, implied 8% upside to Monday's closing price.

With much of that upside set to be realized Tuesday, it remains to be seen whether the earnings boost will turn analysts more bullish.

The company's earnings on Feb.2 and in particular its guidance for 2026 will be key in getting Wall Street off the fence.

Write to Callum Keown at callum.keown@dowjones.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

January 13, 2026 05:51 ET (10:51 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.